Berlin - Delayed Quote EUR

Bone Therapeutics SA (BT1.BE)

0.0016

-0.0001

(-5.88%)

As of 2:15:06 PM GMT+2. Market Open.

BioSenic provides third quarter 2024 Business Update

BioSenic provides third quarter 2024 Business Update BioSenic is actively seeking one or more new assets through a merger or acquisition process Mont-Saint-Guibert, Belgium, October 28, 2024, 7.00 am CEST – Regulated Information - BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases, as well as cell repair, today provides its business update for the third quarter, ended 30 September 2024. Key highlights In July 2024

GlobeNewswire 6 months ago

BIOS.PA

BIOS.BR
BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD.

REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, October 7, 2024, 7:00 CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from ABO Infinium Americas OpCo LTD. The details of the transparency notification are set out below and the full text of the transparen

GlobeNewswire 7 months ago

BIOS.BR

BIOS.PA
BioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the composition of its board of directors

PRIVILEGED INFORMATION Biosenic and Global Tech Opportunities 15 ("GTO 15") have entered into an amendment to the convertible bonds ("CB") agreement securing a further EUR 1.5 million of the programme, including at least two tranches of EUR 0.2 million net each.François Rieger and Véronique Pomi-Schneiter resign from their positions as CEO, chairman and executive director and non-executive director respectively, to focus on Medsenic. Finsys Management SRL, represented by its permanent representa

GlobeNewswire 7 months ago

BIOS.PA

BIOS.BR
BioSenic reports half year 2024 results

REGULATED INFORMATIONThe interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can be accessed on the website of Biosenic in the section ‘Financial reports'. BioSenic publishes its interim financial report in English. A French translation of the report will also be made available. In the event of differences between the English and the French version of the report

GlobeNewswire 7 months ago

BIOS.BR

BIOS.PA
Véronique Pomi-Schneiter stands down as BioSenic's Deputy CEO

PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, September 17, 2024 7.00pm CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases, today announces that Véronique Pomi-Schneiter resignes for personal reasons as Deputy CEO of BioSenic. Véronique Pomi-Schneiter will fully assist in the transition process and continue to serve as non-executive member of the board of directors of BioSenic, as well as an executive

GlobeNewswire 7 months ago

BIOS.PA

BIOS.BR
Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in relapsing-remitting multiple sclerosis

INSIDE INFORMATION Medsenic's experimental drug, arsenic trioxide, can now be investigated for the treatment of multiple sclerosis through repeated cycles of administration by multiple routes, including intravenous, oral and other innovating routes of administration. Mont-Saint-Guibert, Belgium, August 14, 2024, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases, today announces that the European Pate

GlobeNewswire 8 months ago

BIOS.PA

BIOS.BR
Medsenic/BioSenic patent granted in Japan for more protection of its therapeutic platform

PRIVILEGED INFORMATION Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration.Enriched IP portfolio protects arsenic trioxide (ATO) use combined with copper ions delivery, which has demonstrated increased therapeutic potential for indications ranging from immune to cancer and infectious diseases. Mont-Saint-Guibert, Belgium, 13 août 2024, 6.00pm CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company

GlobeNewswire 8 months ago

BIOS.BR

BIOS.PA
BioSenic S.A. : Transparency notification received from Mr François Rieger

PRESS RELEASE – REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, July 19, 2024, 6pm CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from Mr François Rieger. The details of the transparency notification are set out below and the full text of the transpare

GlobeNewswire 9 months ago

BIOS.PA

BIOS.BR
BioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHD

Press Release The upcoming Phase 3 trial with ATO is more robust following a new post-hoc analysis. Mont-Saint-Guibert, Belgium, July 18, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases therapy, today announced the final results of a new, detailed post-hoc analysis of the Company's previous Phase 2 clinical trial of ATO for the first-line curative treatment of cGvHD. The analysis will be us

GlobeNewswire 9 months ago

BIOS.PA

BIOS.BR
BioSenic S.A. : Transparency notification received from Véronique Pomi

PRESS RELEASE – REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, July 12, 2024, 6pm CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from Ms Véronique Pomi. The notifications details can be found below and can be consulted on the website of BioSenic, unde

GlobeNewswire 9 months ago

BIOS.BR

BIOS.PA
Medsenic, subsidiary of BioSenic SA, extends key patent to the United States

PRESS RELEASE – PRIVILEGED INFORMATION The developed Medsenic’s composition-of-matter patent family does cover the therapeutic use of arsenic salts and metal ions through various routes of administration.Medsenic’s enriched IP portfolio is aimed at protecting medications involving the combination of arsenic trioxide (ATO) and copper ions, which have demonstrated increased therapeutic potential for indications ranging from immune to cancer and to infectious diseases. Mont-Saint-Guibert, Belgium,

GlobeNewswire 10 months ago

BIOS.PA

BIOS.BR
Medsenic, BioSenic’s subsidiary, signed a new set of licensing and commercialization agreements with Phebra PTY Ltd.

PRESS RELEASE – PRIVILEGED INFORMATION The adapted supply and commercialization conditions to better achieve the development of the first oral formulation of arsenic trioxide for the treatment of cGvHD should provide the best chances for final market access. Mont-Saint-Guibert, Belgium, July 2, 2024, 7.00am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS,

GlobeNewswire 10 months ago

BIOS.PA

BIOS.BR
BioSenic S.A. : Information on the total number of voting rights and shares

PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, June 28, 2024, 7.00 am CET – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007 on the publication of major sha

GlobeNewswire 10 months ago

BIOS.PA

BIOS.BR
BioSenic signs a new subscription agreement for a maximum of EUR 2.1M in convertible bonds

PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 21, 2024 6.00pm CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces that it has signed a new subscription agreement for a maximum EUR 2.1 million convertible bonds ("CBs") facility, arranged by ABO Securities through its affiliated entity Global Tech Opportunities 15 ("GTO 15"). GTO 15 has committed to s

GlobeNewswire 10 months ago

BIOS.PA

BIOS.BR
The Enterprise Court of Nivelles approves the BioSenic restructuring plan

PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 14, 2024 7.00am CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases, as well as cell repair, announces that it has received the homologation judgment for the restructuring plan filed with the Enterprise Court of Nivelles. This homologation judgment makes the plan binding on all deferred creditors, and the measures provided for therein w

GlobeNewswire 10 months ago

BIOS.BR

BIOS.PA
BioSenic to host Annual General Meeting on July 12, 2024

PRESS RELEASE – REGULATED INFORMATION Preliminary documents for the Annual General Meeting have been made available on company’s website Mont-Saint-Guibert, Belgium, June 12th, 2024 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the annual general meeting t

GlobeNewswire 10 months ago

BIOS.PA

BIOS.BR
BioSenic announces 2023 full year results

PRESS RELEASE - REGULATED INFIRMATION BioSenic stopped the patient recruitment for its Phase 2b ALLOB trial in mid-2023. BioSenic has prepared a global restructuring plan covering the years 2024-2032 and will actively pursue follow-up actions. BioSenic expects to use the proceeds from anticipated future fundraising as a priority to progress its Phase 3 clinical trial in cGvHD. Mont-Saint-Guibert, Belgium, June 6, 2024, 9:00pm CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stag

GlobeNewswire 11 months ago

BIOS.PA

BIOS.BR
BioSenic S.A. : Positive vote of the majority of creditors in favor of the global restructuring plan of BioSenic covering the years 2024-2032, at the Enterprise Court of Nivelles

PRESS RELEASE - PRIVILEGED INFORMATION After a recent circular consultation of the creditors, based on XX 83/23 of the Economic Law Code (ELC), the Enterprise Court of Nivelles registers today the positive votes of the majority of creditors on the Restructuration Plan presented by BioSenic and its restructuration practitioner, Maître Yves Brulard. Mont-Saint-Guibert, Belgium, 27 May 2024, 5:00pm CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in seriou

GlobeNewswire 11 months ago

BIOS.PA

BIOS.BR
BioSenic provides First Quarter 2024 Business Update

PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, May 24, 2024, 17.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces its business update for the first quarter, ended 31 March 2024. Key highlights In January 2024, BioSenic signed a new subscription agreement for a maximum EUR 1.2 million convertible bonds facility, arranged by ABO Securities through its

GlobeNewswire 11 months ago

BIOS.PA

BIOS.BR

Performance Overview

Return	BT1.BE	BEL 20 (^BFX)
YTD	-72.88%	+4.66%
1-Year	-90.36%	+10.71%
3-Year	-99.49%	+11.47%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bone Therapeutics SA (BT1.BE)

BioSenic provides third quarter 2024 Business Update

BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD.

BioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the composition of its board of directors

BioSenic reports half year 2024 results

Véronique Pomi-Schneiter stands down as BioSenic's Deputy CEO

Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in relapsing-remitting multiple sclerosis

Medsenic/BioSenic patent granted in Japan for more protection of its therapeutic platform

BioSenic S.A. : Transparency notification received from Mr François Rieger

BioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHD

BioSenic S.A. : Transparency notification received from Véronique Pomi

Medsenic, subsidiary of BioSenic SA, extends key patent to the United States

Medsenic, BioSenic’s subsidiary, signed a new set of licensing and commercialization agreements with Phebra PTY Ltd.

BioSenic S.A. : Information on the total number of voting rights and shares

BioSenic signs a new subscription agreement for a maximum of EUR 2.1M in convertible bonds

The Enterprise Court of Nivelles approves the BioSenic restructuring plan

BioSenic to host Annual General Meeting on July 12, 2024

BioSenic announces 2023 full year results

BioSenic S.A. : Positive vote of the majority of creditors in favor of the global restructuring plan of BioSenic covering the years 2024-2032, at the Enterprise Court of Nivelles

BioSenic provides First Quarter 2024 Business Update

Performance Overview